Murphy SA, et al. - Among patients with stable atherosclerotic disease receiving statin therapy, researchers assessed the impact of evolocumab on total cardiovascular events. In this prespecified secondary analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) trial, 27,564 patients (mean age 63 years) with stable atherosclerotic disease on statin therapy were included. Investigators found that adding the PCSK9 inhibitor evolocumab to statin therapy improved clinical outcomes with significant decreases in total primary end point events, driven by reductions in myocardial infarction, stroke, and coronary revascularization. Evolocumab vs placebo prevented more than double the number of events compared to analyzing only first events. These data provide further support for preventing recurrent cardiovascular events by continuing aggressive lipid-lowering therapy.